DAX19.323 +0,9%ESt504.789 +0,7%MSCIW3.767 +0,4%Dow44.320 +1,0%Nas19.008 +0,2%Bitcoin95.325 +1,3%Euro1,0414 -0,6%Öl75,02 +0,9%Gold2.706 +1,4%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 MicroStrategy 722713 Tesla A1CX3T Rheinmetall 703000 Bayer BAY001 Siemens Energy ENER6Y EVOTEC 566480 Volkswagen (VW) vz. 766403 Amazon 906866 Deutsche Telekom 555750 NEL ASA A0B733 Mercedes-Benz Group (ex Daimler) 710000 Coinbase A2QP7J Deutsche Bank 514000 Palantir A2QA4J
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Börsen in der Gewinnzone -- DAX geht deutlich fester ins Wochenende -- Bitcoin knapp vor 100.000 US-Dollar -- Chef der US-Börsenaufsicht tritt ab -- RWE, Secunet, NEL im Fokus
Top News
Neues Rekordhoch bei rund 99.600 US-Dollar: Bitcoin verharrt knapp unter 100.000-Dollar-Marke Neues Rekordhoch bei rund 99.600 US-Dollar: Bitcoin verharrt knapp unter 100.000-Dollar-Marke
Diese Aktien empfehlen Experten zu kaufen Diese Aktien empfehlen Experten zu kaufen
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

AB SCIENCE Aktie

NeuKaufenVerkaufen
0,7900 EUR -0,0010 EUR -0,13 %
STU
0,7900 EUR -0,0320 EUR -3,89 %
PAR
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.47,54 Mio. EUR

Div. Rendite0,00%

WKNA1CXBG

ISINFR0010557264

SymbolABSCF

AB SCIENCE Aktien News

DatumMeistgelesen
GlobeNewswireAB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease
GlobeNewswireAB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
GlobeNewswireAB Science: Revenues for the first half of 2024 and update on AB Science’s activities
Wer­bungAB SCIENCE-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
GlobeNewswireAB Science announces a slight delay in the publication of its 2024 half-year financial report
GlobeNewswireAB Science provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement
GlobeNewswireAB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024
GlobeNewswireAB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19
GlobeNewswireAB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
GlobeNewswireAB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS
GlobeNewswireAB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
GlobeNewswireAB Science reports its revenues for the year 2023 and provides an update on its activities
GlobeNewswireAB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036
GlobeNewswireAB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science
GlobeNewswireAB Science announces a slight delay in the publication of its 2023 annual financial report
GlobeNewswireAB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS
GlobeNewswireAB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease
GlobeNewswireAB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development
GlobeNewswireAB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company
GlobeNewswireAB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
GlobeNewswireAB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
GlobeNewswireAB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS
GlobeNewswireAB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency
GlobeNewswireAB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosis
GlobeNewswireAB Science will host a live webcast on Thursday November 30, 2023, from 3pm to 4pm CET, to present the masitinib development program in sickle cell disease
GlobeNewswireAB Science: The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”
GlobeNewswireAB Science today reports its revenues for the first half of 2023 and provides an update on its activities
GlobeNewswireAB Science provides an update on the EMA timetable for examination of the masitinib marketing authorization application in ALS
GlobeNewswireAB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)
GlobeNewswireAB Science announces issuance of a Canadian patent for masitinib in the treatment of ALS with protection until 2037
GlobeNewswireAB Science summarizes key messages from its participation to a panel discussion at the 2023 ALS Drug Development Summit
GlobeNewswireAB Science announces that Health Canada has resumed its review of the New Drug Submission for masitinib in amyotrophic lateral sclerosis, following issuance of a screening acceptance letter
GlobeNewswireAB Science reports its revenues for the year 2022 and provides an update on its activities
GlobeNewswireAB Science - Summary of the presentation on masitinib in ALS delivered at 2023 AAN Annual Meeting
GlobeNewswireAB Science announces the success of its capital increase by private placement for an amount of 15 million euros
GlobeNewswireAB Science announces the implementation of a new strategy and the launch of a capital increase
GlobeNewswireAB Science announces masitinib patent granted in Japan for the treatment of amyotrophic lateral sclerosis, strengthening the Company’s intellectual property position until 2037
GlobeNewswireAB Science: Results of masitinib in ALS selected for a scientific platform presentation at the AAN 2023, including long-term survival analysis and a new analysis of patient population with no complete
GlobeNewswireAB Science announces that it has submitted its response to the day 120 questions in the EMA regulatory review of masitinib in amyotrophic lateral sclerosis and clarifies the new timeline for respondin
GlobeNewswireAB Science will host a live webcast on its microtubule destabilizer agents (MDA) platform on Thursday March 16, 2023, from 6pm to 7pm CET
GlobeNewswireAB Science reports a first complete bone marrow response in a relapsed refractory acute myeloid leukemia patient from the very low dose arm of its AB8939 Phase I/II clinical trial (AB18001)

AB SCIENCE News

AB SCIENCE News: auf dieser Seite finden Sie alle AB SCIENCE News und Nachrichten zur AB SCIENCE Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch AB SCIENCE News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um AB SCIENCE News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.